Background The risk of pancreatitis with sitagliptin use in routine care remains to be
established in older patients. We aimed to determine this risk in older adults who were newly …

Purpose To evaluate the risk of acute pancreatitis hospitalization with sitagliptin use in
patients with type 2 diabetes mellitus (T2DM). Methods This retrospective cohort analysis …

Objective The aim of this study was to evaluate the safety and tolerability of sitagliptin 100
mg/day in elderly patients with type 2 diabetes. Design A post hoc pooled analysis of 25 …

OBJECTIVE Limited data exist regarding safety and efficacy of antihyperglycemic drugs in
older patients with type 2 diabetes. The Trial Evaluating Cardiovascular Outcomes with …

Background There is still lack of definite evidence to establish the association between
sitagliptin use and acute pancreatitis. The study aimed to test this issue in Taiwan. Methods …

Introduction In the USA, 45% of patients with type 2 diabetes mellitus (T2 DM) are elderly (≥
65 years old). In general, use of sulfonylurea increases with patient age as does the …

Aim This study was designed to determine if differences in baseline characteristics of
patients with type 2 diabetes mellitus (T2DM) being treated with sitagliptin vs. other oral …

Abstract Aims/Introduction To investigate the efficacy and safety of sitagliptin in elderly
patients with type 2 diabetes mellitus, with a focus on hypoglycemia. Materials and Methods …

Background Sitagliptin, the first dipeptidyl peptidase-4 inhibitor, has demonstrated efficacy
and safety as monotherapy and as add-on therapy to oral antidiabetic agents or insulin …

Background There have only been a few reports about use of dipeptidyl peptidase 4 (DPP-
4) inhibitors in elderly patients with type 2 diabetes mellitus (T2DM), suggesting that the …